Endo pays $2.3m to settle states antitrust claims
22-07-2019
Endo resolves FTC allegations over Lidoderm and Opana ER
24-01-2017
OleksandrShnuryk / Shutterstock.com
Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Endo, Amneal, Impax, antitrust, generic, class action lawsuit
